Investigators are conducting a randomized, two-period crossover trial evaluating a novel targeted biologic therapy for chronic spontaneous urticaria. The initial power analysis determined that a total of 40 patients (20 receiving the biologic followed by placebo, and 20 receiving placebo followed by the biologic) would provide 90% power to detect a clinically significant reduction in symptom severity scores at a two-tailed of 0.05.
Following the initiation of the trial, an interim pharmacokinetic analysis reveals that the biologic has an unexpectedly long half-life. This results in a profound carryover effect that extends well beyond the planned 6-week washout period. To preserve the integrity of the data, the trial steering committee decides to discard all Period 2 data entirely. The study will now be analyzed as a standard two-arm parallel randomized controlled trial using exclusively the Period 1 data (20 patients in the biologic arm and 20 patients in the placebo arm).
Assuming the true effect size of the biologic remains unchanged, which of the following is the most likely statistical consequence of this protocol modification?
- The statistical power of the study will decrease primarily because the analysis must now incorporate inter-subject rather than intra-subject varianceAnswer
- BThe probability of a Type II error will decrease because removing the carryover data eliminates a confounding effect modifier
- CThe statistical power of the study will remain unchanged provided the investigators transition from a paired statistical test to an independent statistical test
- DThe probability of a Type I error will increase because the positive predictive value of the study findings changes with a reduced sample size
- EThe statistical power will increase because the premature closure of the second period prevents the dilution of the treatment effect by cognitive bias
Answer
When the trial is converted to a parallel-group design, the biologic group is now compared to a completely different group of people (the placebo group). The analysis (such as an independent samples t-test) must now incorporate inter-subject variance, which accounts for the natural physiological differences between different human beings. This variance is substantially larger. The combination of utilizing a larger variance term and halving the total number of outcome measurements drastically reduces the statistical power of the study and increases the risk of a Type II error.